Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Wave Life Sciences, Duchenne muscular dystrophy
Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
Wave Life Sciences gains on data for Duchenne therapy
Wave Life Sciences (NASDAQ:WVE) added ~8% premarket Tuesday after the RNA therapeutics company announced interim data from a Phase 2 trial for WVE-N531, an experimental therapy for a neuromuscular disorder known as Duchenne muscular dystrophy (DMD).
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
Wave Life Sciences Shares Climb Premarket on Duchenne Study Data
Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy.
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.
FierceBiotech
11h
Wave surfs DMD success to regulators' doors, sending stock up
Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...
4d
on MSN
Doctors Said These Women’s Mutated Genes Wouldn’t Harm Them
The embryos were female, and Jenssen remembers the doctors assuring her that, because the Duchenne mutation is linked to the ...
WTVC
6d
6-year-old Tennessee boy denied potentially life-saving gene therapy by insurance company
Six-year-old Cooper Wood was diagnosed with Duchenne muscular dystrophy earlier this year. When his parents applied for a one ...
Couriermail
7d
12-year-old boy with muscular dystrophy banned from favourite hobby due to new rule
Brodie Pankhurst suffers from
Duchenne
muscular
dystrophy
, which progressively weakens his muscles. The cruel illness ...
4d
Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy
Neu refix granted orphan disease designation (ODD) & rare pediatric disease designation (RPDD) by US FDA for treatment of ...
18h
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing ...
charitytoday.co.uk
13d
NorthStar: 20 Years of Support for People with Duchenne Muscular Dystrophy
Muscular Dystrophy UK is the leading charity for more than 110,000 children and adults in the UK living with one of over 60 ...
7d
6-year-old Tennessee boy denied life-saving gene therapy by insurance company
Six-year-old Cooper Wood was diagnosed with Duchenne muscular dystrophy earlier this year. When his parents applied for a one ...
5h
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Wave Life Sciences
Food and Drug Administration
Capricor
WVE-N531
Feedback